학술논문

Follow-up plasma apolipoprotein E levels in the Australian Imaging, Biomarkers and Lifestyle Flagship Study of Ageing (AIBL) cohort
Document Type
Academic Journal
Source
Alzheimer's Research & Therapy. February 20, 2015, Vol. 7 Issue 1
Subject
Medical research
Medicine, Experimental
Enzyme-linked immunosorbent assay -- Research
Advertising executives -- Research
Apolipoproteins -- Research
Enzymes -- Research
Biological markers -- Research
Diagnostic imaging -- Research
Health
Diagnosis
Care and treatment
Research
Risk factors
Language
English
ISSN
1758-9193
Abstract
Introduction Alzheimer's disease (AD) is a growing socioeconomic problem worldwide. Early diagnosis and prevention of this devastating disease have become a research priority. Consequently, the identification of clinically significant and sensitive blood biomarkers for its early detection is very important. Apolipoprotein E (APOE) is a well-known and established genetic risk factor for late-onset AD; however, the impact of the protein level on AD risk is unclear. We assessed the utility of plasma ApoE protein as a potential biomarker of AD in the large, well-characterised Australian Imaging, Biomarkers and Lifestyle Study of Ageing (AIBL) cohort. Methods Total plasma ApoE levels were measured at 18-month follow-up using a commercial bead-based enzyme-linked immunosorbent assay: the Luminex xMAP human apolipoprotein kit. ApoE levels were then analysed between clinical classifications (healthy controls, mild cognitive impairment (MCI) and AD) and correlated with the data available from the AIBL cohort, including but not limited to APOE genotype and cerebral amyloid burden. Results A significant decrease in ApoE levels was found in the AD group compared with the healthy controls. These results validate previously published ApoE protein levels at baseline obtained using different methodology. ApoE protein levels were also significantly affected, depending on APOE genotypes, with [epsilon]2/[epsilon]2 having the highest protein levels and [epsilon]4/[epsilon]4 having the lowest. Plasma ApoE levels were significantly negatively correlated with cerebral amyloid burden as measured by neuroimaging. Conclusions ApoE is decreased in individuals with AD compared with healthy controls at 18-month follow-up, and this trend is consistent with our results published at baseline. The influence of APOE genotype and sex on the protein levels are also explored. It is clear that ApoE is a strong player in the aetiology of this disease at both the protein and genetic levels.
Author(s): Veer B Gupta[sup.1,2] , Andrea C Wilson[sup.1,2] , Samantha Burnham[sup.3] , Eugene Hone[sup.1,2] , Steve Pedrini[sup.1,2] , Simon M Laws[sup.1,2,4] , Wei Ling Florence Lim[sup.1,2] , Alan Rembach[sup.5] , [...]